About the Authors

M. Cris Silva-Santisteban

Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom

Isaac M. Westwood

Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom

Kathy Boxall

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Nathan Brown

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Sam Peacock

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Craig McAndrew

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Elaine Barrie

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Meirion Richards

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Amin Mirza

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Antony W. Oliver

Current address: MRC Genome Damage and Stability Centre, University of Sussex, Brighton, Sussex, United Kingdom

Affiliation Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom

Rosemary Burke

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Swen Hoelder

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Keith Jones

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

G. Wynne Aherne

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Julian Blagg

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Ian Collins

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Michelle D. Garrett

Affiliation Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom

Rob L. M. van Montfort

Rob.vanMontfort@icr.ac.uk

Affiliations Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom, Division of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom

Competing Interests

The authors are current or former employees of The Institute of Cancer Research, which has a commercial interest in the development of checkpoint kinase inhibitors. The authors confirm that there are no patents relating to materials pertinent to this article. The authors’ commercial interest in the development of checkpoint kinase inhibitors does not alter their adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: MCSS IMW KB NB CM EB AM MDG IC RLMvM. Performed the experiments: MCSS IMW KB NB SP CM EB MR AM. Analyzed the data: MCSS IMW KB SP MR AWO RB SH KJ GWA JB IC MDG RLMvM. Contributed reagents/materials/analysis tools: AWO IC SH KJ JB RB GWA RLMvM. Wrote the paper: MCSS IMW RLMvM.